

## CORPORATE NEWS

**AlzChem Group AG**  
Dr.-Albert-Frank-Str. 32  
83308 Trostberg  
Germany

[www.alzchem.com](http://www.alzchem.com)

**Sabine Sieber**  
Investor Relations

T +49 8621 86-2888  
F +49 8621 86-502888  
[ir@alzchem.com](mailto:ir@alzchem.com)

### **AlzChem Group AG achieves record Q1 sales**

- **Highest Q1 sales in the company's history of EUR 104.3 million (+10.1%)**
- **Strong EBITDA growth of 35.8% to EUR 16.7 million**
- **Consolidated result rises significantly by 79.3% to EUR 7.9 million**
- **Outlook 2021: Sales and EBITDA expected at upper end of forecast**

Trostberg, May 6, 2021 – AlzChem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, started the fiscal year 2021 with a strong performance. At EUR 104.3 million, the highest Q1 sales in the company's history were achieved. This record figure represents an improvement of 10.1% compared to the previous year's quarterly figure of EUR 94.7 million. In the Specialty Chemicals segment, AlzChem achieved sustained growth rates for Creapure<sup>®</sup>, which are the result of the successful strategic realignment of the company's market presence in the field of dietary supplements. Pharmaceutical (e.g. Bioselect<sup>®</sup>) and agro-specialty products (e.g. Dormex<sup>®</sup>) also performed very well, with global shipments at a stable high level. The Basics & Intermediates segment contributed similarly high absolute sales to Group sales growth in the first quarter of 2021 as the Specialty Chemicals segment. Demand was encouraging across the board for AlzChem solutions for hot metal desulfurization and acetylene production, through Perlka<sup>®</sup> for farmers and dicyandiamide as a key raw material in the pharmaceutical industry, to the NITRALZ<sup>®</sup> product range.

As well as sales, AlzChem was also able to drive profit growth and increase earnings before interest, taxes, depreciation and amortization (EBITDA) even at a far disproportionate rate. The steep growth in sales, together with the reduction in the cost of materials ratio and the moderate increase in other expense items, led to very pleasing EBITDA growth of 35.8% to EUR 16.7 million, equivalent to an EBITDA margin of 16.0% (Q1 2020: 13.0%). Consolidated result improved even more strongly, by 79.3% from EUR 4.4 million to EUR 7.3 million.

Andreas Niedermaier, CEO of AlzChem Group AG: "Our strong growth is based on a very broad foundation – both in terms of our product range and across the various regions. Our new developments are also doing excellently, as are our products, which score particularly well with sustainability arguments."

Against the background of the very successful first quarter, the forecast for the full year 2021 is confirmed, but the Management Board expects sales and EBITDA at the upper

end of the range. In terms of sales, AlzChem is forecasting a slightly increasing to increasing development of up to EUR 400 million, and in terms of EBITDA a stable to slightly increasing result of up to EUR 57 million.

The detailed quarterly statement for the first quarter of 2021 is available for download on the website [www.alzchem.com](http://www.alzchem.com) under Investor Relations/Publications/Financial Reports.

### **About AlzChem**

AlzChem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. AlzChem benefits in particular from the three very different global megatrends of sustainability, population growth and healthy aging. AlzChem products offer attractive solutions in a wide range of applications.

The company sees interesting growth prospects for itself above all in the fields of human and animal nutrition, pharmaceuticals, agriculture, fine chemicals, metallurgy and renewable energies. The broad product range includes, for example, dietary supplements, plant growth regulators and precursors for corona tests.

The company employs around 1,630 people at four production sites in Germany and Sweden, and at two sales companies in the USA and China. In 2020, AlzChem generated consolidated sales of around EUR 379 million and EBITDA of around EUR 53.8 million.